1436305
Last Update Posted: 2017-09-27
Recruiting has ended
All Genders accepted | 18 Years-65 Years |
19 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
The purpose of this study was to assess whether a new drug, Nulojix® (belatacept), would minimize serious long term side effects associated with anti-rejection medications while still protecting the new kidney from damage. The researchers also wanted to learn more about the safety of this treatment and long term health of the transplanted kidney.
Dialysis or kidney transplant are the two ways to treat kidney failure. Transplant recipients have to take anti-rejection medications to prevent their immune system (the body's natural defense system against illness) from rejecting their new kidney. Most patients who undergo a kidney transplant must take these anti-rejection medications for the rest of their lives. Taking standard anti-rejection medications for a long time can cause serious side effects, including kidney damage. There would be a benefit to finding new anti-rejection medications that work just as well, but don't damage the kidney.
Eligibility
Relevant conditions:
Kidney Transplantation
Renal Transplantation
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov